Biomedical Engineering Reference
In-Depth Information
with unresectable/metastatic gastrointestinal stromal tumors.
J Clin
2009; 27(19): 3141-3147.
135. Yoo C, Ryu MH, Kang BW, Yoon SK, Ryoo BY, Chang HM,
Oncol
Cross-
sectional study of imatinib plasma trough levels in patients with
advanced gastrointestinal stromal tumors: impact of gastrointestinal
resection on exposure to imatinib.
et al.
J Clin Oncol
2010; 28(9): 1554-
1559.
136. Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED,
Imatinib
pharmacokinetics in patients with gastrointestinal stromal tumour:
a retrospective population pharmacokinetic study over time. EORTC
Soft Tissue and Bone Sarcoma Group.
et al.
Cancer Chemother Pharmacol
2005; 55(4): 379-386.
137. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib.
Clin
2005; 44(9): 879-894.
138. Benjamin RS, Debiec-Rychter M, Le Cesne A, Sleijfer S, Demetri GD,
Joensuu H,
Pharmacokinet
Gastrointestinal stromal tumors II: medical oncology
and tumor response assessment.
et al.
2009; 36(4): 302-311.
139. Maleddu A, Pantaleo MA, Nannini M, Di Battista M, Saponara M, Lolli C,
et al.
Semin Oncol
Mechanisms of secondary resistance to tyrosine kinase inhibitors
in gastrointestinal stromal tumours (Review).
Oncol Rep
2009; 21(6):
1359-1366.
140. Joensuu H, Eriksson M, Hatrmann J, Sundby Hall K, Schutte J, Reichardt
A, Schlemmer M, Wardelmann E, Ramadori G, Al-Batran S, NIlsson BE,
Monge O, Kallio R, Sarlomo-Rikala M, Bono P, Leinonen M, Hohenberger
P, Alvegard T, Reichardt P , editor. Twelve versus 36 months of adjuvant
imatinib (IM) as treatment of operable GIST with a high risk of
recurrence: Final results of a randomized trial (SSGXVIII/AIO). 2011
ASCO Annual Meeting; 2011; Chicago, IL.
141. Frolov A, Chahwan S, Ochs M, Arnoletti JP, Pan ZZ, Favorova O,
Response markers and the molecular mechanisms of action of Gleevec
in gastrointestinal stromal tumors.
et al.
Mol Cancer Ther
2003; 2(8): 699-
709.
142. Ochs MF, Rink L, Tarn C, Mburu S, Taguchi T, Eisenberg B,
Detection
of treatment-induced changes in signaling pathways in gastrointestinal
stromal tumors using transcriptomic data.
et al.
Cancer Res
2009; 69(23):
9125-9132. PMCID: 2789202.
143. Tarn C, Skorobogatko YV, Taguchi T, Eisenberg B, von Mehren M, Godwin
AK. Therapeutic effect of imatinib in gastrointestinal stromal tumors:
AKT signaling dependent and independent mechanisms.
Cancer Res
2006; 66(10): 5477-5486.
